Set to push on with the most extensive trials yet for its lead drug candidate IHL-42X, Incannex Healthcare is firming up its credentials to deliver a sea change in the treatment of obstructive sleep apnoea (OSA).
OSA’s symptoms are a reduction – or in some cases a complete stopping – of normal airflow in breathing during sleep. The condition presents as snoring, and in severe cases, patients wake up breathless. Immediate effects are deceptively innocent – sleepiness, affecting performance and mood. For drivers and machinery operators the effects can be deadly. Long-term consequences include an increased risk of heart disease and mental health disorders.
With the company’s mission to focus on unmet medical needs, Dr Mark Bleackley, Incannex’s Chief Scientific Officer, says there are few more deserving examples of a condition requiring alternative treatment. Talking to Edison, he said:
‘Estimates suggest OSA affects about a billion people, around 20% of the world’s adult population. It’s on the increase and there are no pharmacotherapies available.’
Key to Incannex’s plan is to disrupt the existing non-pharmacotherapy treatments that are expensive and have poor patient compliance – most often, mechanical devices – continuous positive airway pressure (CPAP) machines, dental alterations and surgery as a fall back. The sleep apnoea device market alone was worth about $3.9 billion in 2021 according to Evolve Business Intelligence.
IHL-42X is in fact two drugs – a cannabinoid combination product – and the result of three years of research under Dr Bleackley’s direction.
‘It’s made up of two pharmaceutical ingredients – acetazolamide, a carbonic anhydrase inhibitor, and dronabinol, a synthetic form of THC. Both have clinical evidence to support their therapeutic effect in OSA,’ said the CSO.
‘Each targets different components of the disease and that was the basis for our hypothesis that the combination would be synergistic.’
Data from the first proof-of-concept trial has confirmed the hypothesis was correct: that IHL-42X reduced the number of ‘apnoeas’ (pauses in breathing), and ‘hypopneas’ (incidents of shallow breathing), but the synergy of the product’s ingredients created an additional win – the foundation of its IP protection.
2023 will see Incannex’s research scale up significantly. Bioavailability and bioequivalence studies will roll out before the company files an IND with the FDA for Phase II/III study, when multiple sites across North America and Europe will see more than 400 patients involved over 12 months.
‘This is about disrupting a multibillion dollar market and gaining value for investors in the short, mid and long-term,’ says Incannex CEO, Joel Latham,’ but it’s also about giving OSA patients a choice.’
‘We want to develop novel therapies to make a difference to the lives of millions of people, giving them a far more convenient and effective treatment.’
Find out more about IHL-42X and Incannex Healthcare’s investment case by reading Edison’s latest update and initiation report
Edison offers investor relations, consulting and research publication services to paying clients. In accordance with Section 17(b) of the US Securities Act of 1933, please note the following important disclosures relating to Edison and its client relationship with Lepidico (the “Company”).
Edison is engaged by the Company on a paid basis for investor relations services and this communication relates to those services. In connection with its investor relations engagement by the Company, Edison’s standard fees are $20,000 per month. Additional compensation may have accrued since the publication of this notice.
In addition, Edison is engaged by the Company to separately provide investment research coverage of its stock. In connection with its investment research coverage, Edison’s standard fees are £60,000 pa. Additional compensation may have accrued since the publication of this notice. No compensation relating to Edison’s investment research coverage is in any way contingent upon any positive opinions or conclusions in its research reports.
Edison’s investor relations services are independent of its research services, although Edison’s investor relations activities may utilize published Edison research as a source, among others, in connection with its activities. Edison’s investor relations and investment research personnel regularly, but separately, interact with the Company. All source materials relating to any investor relations materials of Edison should be considered to be directly attributable to information provided to Edison by the Company or the third-party sources noted in the communication. While third-party information used in the publication of Edison’s communications is typically compiled from publicly available sources that are believed to be accurate, complete and reliable, Edison does not guarantee the accuracy or completeness of information contained therein, and typically does not independently verify such information.
NOTE THAT ALL INVESTMENTS ARE SUBJECT TO INHERENT RISK AND ANY INVESTMENT IN THE COMPANY IS SUBJECT TO SIGNIFICANT RISKS THAT SHOULD BE ASSESSED BY ANY INVESTOR AND THEIR ADVISORS. PLEASE CLOSELY REVIEW THE COMPANY’S AVAILABLE PUBLIC DISCLOSURES, INCLUDING RISK FACTORS FOR SPECIFIC CONSIDERATION, WHICH ARE AVAILABLE THROUGH THE COMPANY’S INVESTOR RELATIONS WEBSITE, LINKED ABOVE.
This communication may include forward-looking statements that are subject to risks and uncertainties. Factors that could cause a company’s actual results and financial condition to differ from expectations include, without limitation: political uncertainty, changes in general economic conditions that adversely affect the level of demand for the company’s products or services, changes in international and domestic financial markets and in the competitive environment, and other factors relating to the foregoing. All forward-looking statements relating to this communication are qualified in their entirety by this cautionary statement.
Edison is neither a FINRA-registered broker-dealer nor an SEC-registered investment adviser and does not provide any investment advisory or banking services. Edison’s investment research reports are bona fide publications of general and regular circulation offering impersonal investment-related advice, not tailored to a specific investment portfolio or the needs of current and/or prospective subscribers. Edison does not offer or provide personal advice and its research provided is for informational purposes only. No mention of a particular security in any Edison communication constitutes a solicitation or recommendation to buy, sell or hold that or any security, or that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person.
Edison has a restrictive policy relating to personal dealing and conflicts of interest. Edison does not conduct any investment business and, accordingly, does not itself hold any positions in the securities mentioned in this report. However, the respective directors, officers, employees and contractors of Edison may have a position in any or related securities mentioned in this report, subject to Edison’s policies on personal dealing and conflicts of interest.
Get access to the very latest content matched to your personal investment style.